Johnson & Johnson, parent company of the DePuy Synthes Companies and Animas Corporation, both of West Chester, announced sales of $18.1 billion for the first quarter of 2014 – an increase of 3.5 percent compared to the first quarter of 2013.

DePuy Synthes offers a comprehensive portfolio of orthopaedic and neuro products and services for joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, medical power tools and biomaterials.

Animas Corp. is focused on diabetes care with insulin delivery products such OneTouch Ping glucose management system and the inset family of all-in-one infusion sets, which work with any pump.

Operational results increased 5.3 percent and the negative impact of currency was 1.8 percent. Domestic sales increased 2.2 percent. International sales increased 4.5 percent, reflecting operational growth of 7.9 percent and a negative currency impact of 3.4 percent.

“Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products,” said Alex Gorsky, chairman and chief executive officer. “Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results.”

The company increased its earnings guidance for full-year 2014 to $5.80 – $5.90 per share, excluding the impact of special items.

The two local firms had an impact on overall company growth. J&J says primary contributors to operational growth were sales of products in the orthopaedics business; the specialty surgery business; and Biosense Webster’s electrophysiology products in the Cardiovascular Care business.

Sales results in the U.S. Diabetes Care business were negatively impacted by price declines associated with the implementation of Medicare competitive bidding in mail order and retail effective July 1, 2013.

Also during the quarter, a binding offer was accepted from The Carlyle Group to acquire the Ortho-Clinical Diagnostics business for approximately $4 billion, subject to customary adjustments. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.

Caring for the world, one person at a time, is a Johnson & Johnson motto. The company embraces research and science – bringing innovative ideas, products and services to advance the health and well-being of people. J&J has approximately 128,300 employees at more than 275 operating companies working with partners in health care.